| abstract |
A method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of Formula I(J) as described in the specification, or a pharmaceutical composition comprising a therapeutically effective amount of the JAK-2 compound of Formula I(J) and a pharmaceutically acceptable carrier, in combination with an active agent selected from of a Raf inhibitor, an EGFR inhibitor, a VEGFR inhibitor, a ErbB2 inhibitor, a BCR-Abl, inhibitor, a Flt3 inhibitor, a Src inhibitor, a c Kit inhibitor, an Akt inhibitor, a Ret inhibitor, an IFG1R inhibitor, an m-Tor inhibitor, a PI3K inhibitior, a PI3Kalpha inhibitor, wherein the mammal is in need of the treatment. |